NVDA
NVIDIA
-- 149.430 TSLA
Tesla
-- 411.050 FUBO
FuboTV
-- 5.060 PLTR
Palantir
-- 75.920 AMD
Advanced Micro Devices
-- 129.550 
ADDED NEWS
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
▪️ProMIS Neurosciences (Nasdaq: PMN) has reported positive top-line data from the first four cohorts of its Phase 1a clinical trial of PMN310 in healthy volunteers for Alzheimer's disease. The results showed:
▪️ProMIS Neurosciences (Nasdaq: PMN) has reported positive top-line data from the first four cohorts of its Phase 1a clinical trial of PMN310 in healthy volunteers for Alzheimer's disease. The results showed:
▪️A favorable safety profile and tolerability across four ascending dose levels
▪️Dose-dependent levels of PMN310 antibody in cerebrospinal fluid (CSF)
Potential for target engagement in Alzheimer's patients
▪️PMN310 was well-tolerated with no serious adverse events observed. The antibody demonstrated dose proportionality in CSF and a half-life of approximately 25 days, supporting monthly dosing. ProMIS plans to advance PMN310 into a Phase 1b study in Alzheimer's patients in the second half of 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Chhavin : With all the positive news stock is down still.
Jaguar8 OP Chhavin : The Private placement is seen as dilution by traders
Chhavin Jaguar8 OP : I purchased at 3.43 at the time I thought it’s a good entry since the company has many good news reported. I will hold
Rafey Jan Jaguar8 OP : @Jaguar8 does that mean additional shares are issued in return of private placement financing or a loan that needs to be paid back.
Jaguar8 OP Rafey Jan : The shares are offered not to public but to institutional investors. It ain’t a loan financing.
Rafey Jan : @Jaguar8 thanks